11 Best Long Term US Stocks to Buy Right Now
The Franklin Templeton report said long-term investing has usually rewarded patient investors. Markets go through rough periods, as recessions and bear markets happen.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Darwin Global Management Abhishek Trehan | 16,805,184 | $2,576,570,811 | -20% | 68.33% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,421,111 | $1,213,500,071 | +13% | 6.97% |
| 3. | D E Shaw D. E. Shaw | 5,625,825 | $919,934,904 | +30% | 0.55% |
| 4. | Citadel Investment Group Ken Griffin | 2,182,571 | $356,894,010 | +89% | 0.06% |
| 5. | Orbis Investment Management William B. Gray | 1,872,824 | $306,244,181 | -56% | 1.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.35 | 1,130 | $74,975.50 | 3,025 | 2025-05-21 | Filing | |
| $66.87 | 1,895 | $126,718.65 | 1,895 | 2025-05-20 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | $177,000.00 | 15,900 | 2022-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $106.97 | 7,975 | $853,085.75 | 273,037 | 2026-05-18 | Filing | |
| $106.39 | 11,836 | $1,259,232.04 | 281,012 | 2026-05-18 | Filing | |
| $105.32 | 5,753 | $605,905.96 | 292,848 | 2026-05-18 | Filing | |
| $116.18 | 8,272 | $961,040.96 | 71,486 | 2026-05-13 | Filing | |
| $116.18 | 5,837 | $678,142.66 | 100,973 | 2026-05-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,150,499 | $3,702,754,770 | 0.24% | |
| 2. | 16,678,146 | $2,727,210,442 | 0.05% | |
| 3. | 13,160,167 | $2,151,950,430 | 0.11% | |
| 4. | 10,371,802 | $1,695,997,063 | 0.08% | |
| 5. | 9,642,131 | $1,576,681,262 | 0.03% |
News See All
10 Stocks With Stunning Gains
Ten stocks boasted strong gains on Tuesday, outperforming a lackluster performance on Wall Street, as investors continued to digest a flurry of strong corporate earnings.
8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Insmed Incorporated (NASDAQ:INSM) Q1 2026 Earnings Call Transcript
Operator: Thank you for standing by. My name is Danica, and I will be your conference operator today.
Billionaire Druckenmiller and Jim Cramer Like These Stocks
Stanley Druckenmiller and Jim Cramer are two of the closely followed voices in financial markets. Though sometimes their stock preferences differ, they always draw widespread investor attention.
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models
TheFly reported on April 16 that Guggenheim Securities increased its price target on INSM from $227 to $230 while maintaining a Buy rating.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
9 Best QQQ Stocks to Buy Now
On April 8, Yung-Yu Ma of PNC joined 'Fast Money' on CNBC to discuss the current market environment and noted that worst-case scenarios are not yet priced into the VIX or oil futures curves.
Billionaire Stan Druckenmiller's 10 Small and Mid-Cap Stock Picks with Huge Upside Potential
Stanley Druckenmiller, the founder of New York-based Duquesne Family Office, oversees a 13F portfolio at his hedge fund that was worth close to $4.5 billion at the end of the fourth quarter of 2025.
Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 - Here's Why
Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target on Insmed Incorporated (NASDAQ:INSM) to $208 from $205 on March 24, reaffirming...
Hedge Fund Resource Center